A Phase 3 interventional study of Ipilimumab and Nivolumab in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 116 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 13 under way, none of them phase 3. Ipilimumab · Carcinoma, Non-Small-Cell Lung.
Among the 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 11 that started in 2017, is one of 10 in phase 3, and was the 21st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →7 of the 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–80
University of Alabama at Birmingham · Sites in United States
Ages 18–89
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
Brown University · Sites in United States
Ages 18+
By country, each count listing its studies:
Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, ipilimumab is the treatment under test here. Read study by study →
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 30 · Phase 3 10
First in 2002; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 719 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 39 across the 47 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 47 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2017, is one of 27 in phase 3, and was the 64th registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
3 of the studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06364917University of Alabama at BirminghamDISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | 2027-04-27 |
| NCT05012254Fundación GECPNivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | 2027-10-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chemotherapy/Biologics combined
Biological: Ipilimumab · Biological: Nivolumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Cisplatin
Chemotherapy Combination
Drug: Carboplatin · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Cisplatin
Specified dose on specified day
Also known as: Yervoy, BMS734016
Specified dose on specified day
Also known as: Opdivo, BMS936558
Specified dose on specified day
Specified dose on specified day
Also known as: Taxol
Specified dose on specified day
Also known as: Alimta
Specified dose on specified day
Also known as: Platinol
Overall Survival (OS)
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
Time frame: From date of randomization to date of death (assessed up to October 2019, approximately 23 months)
Progression Free Survival (PFS) by BICR
PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Objective Response Rate (ORR) by BICR
ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Duration of Response (DoR)
DoR was defined as the time between the date of first confirmed documented response (CR or PR) to the date of the first documented BICR-assessed tumor progression (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who started subsequent therapy (including palliative local therapy) without a prior reported progression were censored at the last evaluable tumor assessments prior to initiation of the subsequent anticancer therapy (including palliative local therapy). Participants who died without a reported prior progression were considered to have progressed on the date of their death. For subjects who neither progressed nor died, DoR was censored on the date of their last evaluable tumor assessment. DoR was evaluated for responders (confirmed CR or PR) only.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Time to Response (TTR)
TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression
ORR was defined as the proportion of randomized participants with a best overall response (BOR) of confirmed complete or partial response per BICR using RECIST v1.1. BOR was assessed from randomization until documented progression, start of palliative local or subsequent anti-cancer therapy-whichever came first. If none occurred, all response data contributed to BOR. For those treated beyond progression, BOR was based on responses before initial RECIST-defined progression. PD-L1 expression was measured via Dako PD-L1 IHC 28-8 pharmDx test as the percentage of tumor cells with membrane staining among ≥100 evaluable cells. Expression was categorized as ≥1%, \<1%, not quantifiable, ≥50%, or 1-49%.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
PFS by BICR by PD-L1 Tumor Cell Expression
PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
OS by PD-L1 Tumor Cell Expression
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
Time frame: From date of randomization to date of death (assessed up to October 2024, approximately 72 months)
PFS by BICR by Tumor Mutational Burden
PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
ORR by BICR by Tumor Mutational Burden
ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)
OS by Tumor Mutational Burden
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
Time frame: From date of randomization to date of death (assessed up to October 2024, approximately 72 months)
| Milestone | Treatment A | Treatment B |
|---|---|---|
| Started | 361 | 358 |
| Completed | 358 | 349 |
| Not completed | 3 | 9 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 |
| Withdrew: Participant withdrew consent | 1 | 3 |
| Withdrew: No longer meets study criteria | 1 | 4 |
| Withdrew: Other reasons | 0 | 2 |
| Milestone | Treatment A | Treatment B |
|---|---|---|
| Started | 358 | 349 |
| Completed | 49 | 100 |
| Not completed | 309 | 249 |
| Withdrew: Disease progression | 184 | 174 |
| Withdrew: Study drug toxicity | 70 | 24 |
| Withdrew: Death | 7 | 1 |
| Withdrew: Adverse event unrelated to study drug | 31 | 27 |
| Withdrew: Request to d/c treatment | 2 | 10 |
| Withdrew: Participant withdrew consent | 4 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative reason by sponsor | 0 | 2 |
| Withdrew: Other reasons | 10 | 5 |
| Withdrew: Not reported | 1 | 0 |
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
| Months | Treatment A | Treatment B |
|---|---|---|
| Overall Survival (OS) | 14.13 (13.24 to 16.16) | 10.74 (9.46 to 12.45) |
PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.
| Months | Treatment A | Treatment B |
|---|---|---|
| Progression Free Survival (PFS) by BICR | 6.74 (5.55 to 8.05) | 5.26 (4.37 to 5.59) |
ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.
| Percentage of Participants | Treatment A | Treatment B |
|---|---|---|
| Objective Response Rate (ORR) by BICR | 38.0 (32.9 to 43.2) | 25.1 (20.7 to 30.0) |
DoR was defined as the time between the date of first confirmed documented response (CR or PR) to the date of the first documented BICR-assessed tumor progression (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who started subsequent therapy (including palliative local therapy) without a prior reported progression were censored at the last evaluable tumor assessments prior to initiation of the subsequent anticancer therapy (including palliative local therapy). Participants who died without a reported prior progression were considered to have progressed on the date of their death. For subjects who neither progressed nor died, DoR was censored on the date of their last evaluable tumor assessment. DoR was evaluated for responders (confirmed CR or PR) only.
| Months | Treatment A | Treatment B |
|---|---|---|
| Duration of Response (DoR) | 13.01 (8.71 to 20.21) | 5.59 (4.37 to 7.10) |
TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.
| Months | Treatment A | Treatment B |
|---|---|---|
| Time to Response (TTR) | 2.53 (1.1 to 52.1) | 1.58 (1.2 to 22.2) |
ORR was defined as the proportion of randomized participants with a best overall response (BOR) of confirmed complete or partial response per BICR using RECIST v1.1. BOR was assessed from randomization until documented progression, start of palliative local or subsequent anti-cancer therapy-whichever came first. If none occurred, all response data contributed to BOR. For those treated beyond progression, BOR was based on responses before initial RECIST-defined progression. PD-L1 expression was measured via Dako PD-L1 IHC 28-8 pharmDx test as the percentage of tumor cells with membrane staining among ≥100 evaluable cells. Expression was categorized as ≥1%, \<1%, not quantifiable, ≥50%, or 1-49%.
| Percentage of Participants | Treatment A | Treatment B |
|---|---|---|
| BASELINE PD-L1 EXPRESSION ≥1% | 42.6 (35.8 to 49.7) | 27.5 (21.5 to 34.1) |
| BASELINE PD-L1 EXPRESSION < 1% | 31.1 (23.4 to 39.6) | 20.2 (13.6 to 28.1) |
| Non-Quantifiable PD-L1 Expression | 36.4 (17.2 to 59.3) | 32.0 (14.9 to 53.5) |
| BASELINE PD-L1 EXPRESSION 1 - 49% | 38.3 (29.8 to 47.3) | 23.6 (15.9 to 32.8) |
| BASELINE PD-L1 EXPRESSION >= 50% | 50.0 (38.3 to 61.7) | 31.6 (22.6 to 41.8) |
PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.
| Months | Treatment A | Treatment B |
|---|---|---|
| < 1% PD-L1 Expression | 5.78 (4.40 to 7.66) | 4.96 (4.21 to 5.78) |
| >= 1% PD-L1 Expression | 6.87 (5.55 to 8.94) | 4.70 (4.24 to 5.55) |
| with 1-49% PD-L1 Expression | 6.74 (4.50 to 8.51) | 5.29 (4.24 to 5.68) |
| with >= 50% PD-L1 Expression | 8.28 (4.44 to 12.48) | 4.53 (4.14 to 5.65) |
| Non-Quantifiable PD-L1 Expression | 6.95 (3.61 to 15.08) | 6.77 (2.83 to 13.83) |
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
| Months | Treatment A | Treatment B |
|---|---|---|
| < 1% PD-L1 Expression | 17.74 (13.67 to 20.27) | 9.79 (7.69 to 13.54) |
| >= 1% PD-L1 Expression | 15.80 (13.77 to 22.18) | 10.89 (9.49 to 13.17) |
| with 1-49% PD-L1 Expression | 15.20 (12.62 to 21.22) | 10.37 (8.67 to 12.35) |
| with >= 50% PD-L1 Expression | 18.91 (13.11 to 29.11) | 12.93 (9.36 to 17.58) |
| Non-Quantifiable PD-L1 Expression | 10.84 (7.16 to 15.57) | 17.05 (8.64 to NA) |
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
| Months | Treatment A | Treatment B |
|---|---|---|
| Overall Survival (OS) | 15.80 (13.93 to 19.71) | 10.96 (9.49 to 12.71) |
PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.
| Months | Treatment A | Treatment B |
|---|---|---|
| ≥ 10 Mutations/MB | 8.94 (5.55 to 13.01) | 4.70 (4.14 to 5.62) |
| < 10 Mutations/MB | 5.62 (4.17 to 7.20) | 5.16 (4.21 to 5.62) |
| Overall | 6.37 (5.36 to 8.21) | 4.96 (4.27 to 5.55) |
| Not Evaluable | 6.74 (4.24 to 9.69) | 5.45 (4.17 to 5.82) |
ORR was defined as the number of randomized participants with a best overall response (BOR) of confirmed CR or PR based on BICR assessments (using RECIST v1.1 criteria), divided by the number of all randomized participants. BOR was recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of initiation of palliative local therapy or the date of initiation of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or palliative local therapy or subsequent anti-cancer therapy, all available response designations contributed to the BOR determination. For participants who continued treatment beyond progression, the BOR was determined based on response designations recorded up to the time of the initial RECIST 1.1 defined progression.
| Percentage of Participants | Treatment A | Treatment B |
|---|---|---|
| ≥ 10 Mutations/MB | 45.5 (35.6 to 55.8) | 29.3 (19.7 to 40.4) |
| < 10 Mutations/MB | 31.6 (23.9 to 40.1) | 27.0 (19.8 to 35.3) |
| Overall | 37.6 (31.4 to 44.1) | 27.9 (22.0 to 34.3) |
| Not Evaluable | 36.4 (27.8 to 45.8) | 21.2 (14.7 to 29.0) |
OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.
| Months | Treatment A | Treatment B |
|---|---|---|
| ≥ 10 Mutations/MB | 15.05 (12.45 to 20.76) | 10.76 (7.85 to 15.41) |
| < 10 Mutations/MB | 16.51 (11.99 to 19.98) | 12.55 (10.38 to 14.92) |
| Overall | 15.57 (13.34 to 19.38) | 12.06 (10.35 to 14.06) |
| Not Evaluable | 17.10 (13.47 to 25.49) | 9.46 (8.15 to 11.79) |
Collected over 30 days after last dose, assessed up to October 2024, approximately 72 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 304/361 (84.2%) | 259/358 (72.3%) | 343/358 (95.8%) |
| Treatment B | 318/358 (88.8%) | 197/349 (56.4%) | 329/349 (94.3%) |
| Event | Treatment A | Treatment B |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 61/358 | 78/349 |
| PneumoniaInfections and infestations | 28/358 | 23/349 |
| AnaemiaBlood and lymphatic system disorders | 11/358 | 18/349 |
| Febrile neutropeniaBlood and lymphatic system disorders | 15/358 | 9/349 |
| DiarrhoeaGastrointestinal disorders | 14/358 | 3/349 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 13/358 | 2/349 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/358 | 11/349 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 11/358 | 5/349 |
| Acute kidney injuryRenal and urinary disorders | 8/358 | 6/349 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/358 | 7/349 |
| Event | Treatment A | Treatment B |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 122/358 | 161/349 |
| NauseaGastrointestinal disorders | 120/358 | 146/349 |
| AstheniaGeneral disorders | 112/358 | 96/349 |
| Decreased appetiteMetabolism and nutrition disorders | 112/358 | 88/349 |
| DiarrhoeaGastrointestinal disorders | 111/358 | 68/349 |
| ConstipationGastrointestinal disorders | 85/358 | 83/349 |
| PruritusSkin and subcutaneous tissue disorders | 85/358 | 11/349 |
| FatigueGeneral disorders | 81/358 | 62/349 |
| RashSkin and subcutaneous tissue disorders | 76/358 | 16/349 |
| VomitingGastrointestinal disorders | 71/358 | 61/349 |
| Age, Continuous(Years) | Treatment A | Treatment B | Total |
|---|---|---|---|
| Median | 65.0 ± 8.3 | 65.0 ± 10.3 | 65.0 ± 9.4 |
| Age, Customized(Count of Participants) | Treatment A | Treatment B | Total |
|---|---|---|---|
| ˂65 years old | 176 | 178 | 49.2 |
| ≥65 and ˂75 years old | 148 | 147 | 41.0 |
| ≥75 years old | 37 | 33 | 9.7 |
| ≥85 years old | 0 | 2 | 0.3 |
| Sex: Female, Male(Participants) | Treatment A | Treatment B | Total |
|---|---|---|---|
| Female | 109 | 106 | 215 |
| Male | 252 | 252 | 504 |
| Ethnicity (NIH/OMB)(Participants) | Treatment A | Treatment B | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 31 | 60 |
| Not Hispanic or Latino | 154 | 158 | 312 |
| Unknown or Not Reported | 178 | 169 | 347 |
| Race (NIH/OMB)(Participants) | Treatment A | Treatment B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 30 | 30 | 60 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 9 |
| White | 322 | 316 | 638 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 8 | 11 |
Showing the first 100 of 116 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Aug 2019, 23 months.
Results were first posted in Sep 2020, 1 year 1 month after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 23 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ipilimumab · Nivolumab
Carcinoma, Non-Small-Cell Lung →